Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma

For detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis, serum α-fetoprotein has been widely used, but its sensitivity has not been satisfactory, especially in small, well-differentiated HCC, and complementary serum marker has been clinically required. Glypican-3 (GPC3), a heparan sulfate proteoglycan anchored to the plasma membrane, is a good candidate marker of HCC because it is an oncofetal protein overexpressed in HCC at both the mRNA and protein levels. In this study, we demonstrated that its NH2-terminal portion [soluble GPC3 (sGPC3)] is cleaved between Arg358 and Ser359 of GPC3 and that sGPC3 can be specifically detected in the sera of patients with HCC. Serum levels of sGPC3 were 4.84 ± 8.91 ng/ml in HCC, significantly higher than the levels seen in liver cirrhosis (1.09 ± 0.74 ng/ml; P < 0.01) and healthy controls (0.65 ± 0.32 ng/ml; P < 0.001). In well- or moderately-differentiated HCC, sGPC3 was superior to α-fetoprotein in sensitivity, and a combination measurement of both markers improved overall sensitivity from 50% to 72%. These results indicate that sGPC3 is a novel serological marker essential for the early detection of HCC.

[1]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[2]  Yusuke Nakamura,et al.  Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. , 2003, Biochemical and biophysical research communications.

[3]  Charles A Powell,et al.  The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. , 2003, American journal of respiratory cell and molecular biology.

[4]  Roger E Bumgarner,et al.  Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. , 2003, Cancer research.

[5]  S. Ishikawa,et al.  Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling , 2003, International journal of cancer.

[6]  S. Hirohashi,et al.  Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinoma , 2003, Hepatology.

[7]  E. Bass,et al.  Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review , 2002, Hepatology.

[8]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[9]  A. Befeler,et al.  Hepatocellular carcinoma: diagnosis and treatment. , 2002, Gastroenterology.

[10]  G. Fu,et al.  Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Filmus,et al.  Glypican-3 expression is silenced in human breast cancer , 2001, Oncogene.

[12]  S. Hirohashi,et al.  Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. , 2001, Journal of hepatology.

[13]  M. Yamamoto,et al.  Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma. , 2001, Anticancer research.

[14]  A. Ryo,et al.  Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas. , 2001, Biochimica et biophysica acta.

[15]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[16]  T. Tsunoda,et al.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.

[17]  J. Filmus,et al.  Glypicans in growth control and cancer. , 2001, Glycobiology.

[18]  P. Johnson,et al.  The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. , 2001, Clinics in liver disease.

[19]  Hong-Yang Wang,et al.  Cloning and expression of MXR7 gene in human HCC tissue. , 2000, World journal of gastroenterology.

[20]  D. Schlessinger,et al.  Frequent silencing of the GPC3 gene in ovarian cancer cell lines. , 1999, Cancer research.

[21]  W. Anderson,et al.  New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma , 1998, Hepatology.

[22]  Wei Cheng,et al.  Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. , 1997, Cancer research.

[23]  A. Schwartz,et al.  Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. , 1997, The Biochemical journal.

[24]  D. Schlessinger,et al.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome , 1996, Nature Genetics.

[25]  J. Filmus,et al.  Identification of a new membrane-bound heparan sulphate proteoglycan. , 1995, The Biochemical journal.

[26]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[27]  K. Taketa.  a-Fetoprotein: Reevaluation , 2005 .

[28]  J. Church,et al.  Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine , 1988, Molecular and cellular biology.

[29]  M. Honda,et al.  Identification of Differentially Expressed Genes in Hepatocellular Carcinoma With cDNA Microarrays , 2022 .